𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases

✍ Scribed by Masahito Shimizu; Seiji Adachi; Muneyuki Masuda; Osamu Kozawa; Hisataka Moriwaki


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
240 KB
Volume
55
Category
Article
ISSN
1613-4125

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Recent studies indicate that receptor tyrosine kinases (RTKs), which play important roles in cell proliferation, are one of the possible targets of green tea catechins (GTCs) in cancer cell growth inhibition. (−)‐Epigallocatechin‐3‐gallate (EGCG), the major catechin in green tea, inhibits cell proliferation and induces apoptosis in various types of cancer cells, including colorectal cancer and hepatocellular carcinoma cells, by blocking the activation of the epidermal growth factor receptor (EGFR) family of RTKs. EGCG inhibits the activation of insulin‐like growth factor‐1 receptor (IGF‐1R) and VEGFR2, the other members of the RTK family, and this effect is also associated with the anticancer and chemopreventive properties of this agent. EGCG suppresses the activation of EGFR in part by altering membrane lipid organization and causing the subsequent inhibition of the dimerization and activation of this receptor. Preliminary trials have shown that GTCs successfully prevent the development and progression of precancerous lesions, such as colorectal adenomas, without causing severe adverse effects. The present report reviews evidence indicating that GTCs exert anticancer and chemopreventive effects by inhibiting the activation of specific RTKs, especially EGFR, IGF‐1R, and VEGFR2, and concludes that targeting RTKs and their related signaling pathways by using tea catechins could be a promising strategy for the prevention of human cancers.


📜 SIMILAR VOLUMES


Targeted inhibition of the epidermal gro
✍ Alessandro Sgambato; Andrea Camerini; Beatrice Faraglia; Raffaele Ardito; Gabrie 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

## Abstract The epidermal growth factor (EGF) plays a role in the development of prostate cancer, which becomes essential after androgen resistance has emerged. The EGF receptor (EGFR) is therefore a potential target for anticancer therapy. We evaluated the effects of ZD1839 (‘Iressa’), an orally a

Epidermal growth factor receptor mutatio
✍ Victor Cohen; Jason S. Agulnik; Celina Ang; Goulnar Kasymjanova; Gerald Batist; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 1 views

## Abstract ## BACKGROUND: Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) in patients with nonsmall cell lung cancer (NSCLC). ## METHODS: The authors tested the possibility that nucleoti